Drug Company Says Failed Trial May Not Be the End for Potential Mesothelioma Drug, According to Surviving Mesothelioma

Share Article

An immunotherapy drug that failed to improve mesothelioma survival in a recent clinical trial may still be used as part of a mesothelioma treatment combination.

Tremelimumab and Mesothelioma

Immunotherapy Drug Fails Trial

We remain confident in tremelimumab’s clinical activity in combination...

The makers of an immunotherapy drug called tremelimumab say they are “disappointed” by its performance as a stand-alone mesothelioma drug, but are still hopeful about its cancer-fighting potential. Surviving Mesothelioma has just posted an article on the announcement. Click here to read it now.

Although mesothelioma patients who were given tremelimumab as a second-or third-line treatment did not see improved survival, manufacturer AstraZeneca says the drug may be more effective in combination with another type of immunotherapy.

“We remain confident in tremelimumab’s clinical activity in combination, as shown in our recently published Study 006 trial of tremelimumab and durvalumab in non-small cell lung cancer,” said AstraZeneca senior vice president Robert Iannone in a statement on the firm’s website.

Patients in the clinical trial of tremelimumab had unresectable mesothelioma and had to have failed at at least one other type of mesothelioma treatment.

“Although tremelimumab will not be used as a stand-alone therapy for mesothelioma, the evidence is good that it may still have value in combination with other immunotherapy drugs or even with chemotherapy,” says Alex Strauss, Managing Editor of Surviving Mesothelioma. “We will continue to follow its progress to keep patients and their families informed.”

To read more about tremelimumab and the recent clinical trial, see Promising Immunotherapy Drug Fails to Improve Mesothelioma Survival, now available on the Surviving Mesothelioma website.

“AstraZeneca reports top-line result of tremelimumab monotherapy trial in mesothelioma”, February 29, 2016, News Release, AstraZeneca website, https://www.astrazeneca.com/our-company/media-centre/press-releases/2016/astrazeneca-reports-top-line-result-of-tremelimumab-monotherapy-trial-in-mesothelioma-29022016.html

For nearly ten years, Surviving Mesothelioma has brought readers the most important and ground-breaking news on the causes, diagnosis and treatment of mesothelioma. All Surviving Mesothelioma news is gathered and reported directly from the peer-reviewed medical literature. Written for patients and their loved ones, Surviving Mesothelioma news helps families make more informed decisions.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Michael Ellis
Cancer Monthy
+1 (919) 570-8595
Email >
Follow us on
Visit website